There have been attempts in the past to ascertain whether any part of the IGF axis (ligands, receptors, or binding proteins) could be used as a reliable biological marker for prostate cancer and prostate cancer metastases with controversial results [62, 63]. This evidence concerns the gene IGF1 and prostate carcinoma.